<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01114490</url>
  </required_header>
  <id_info>
    <org_study_id>0859-039</org_study_id>
    <secondary_id>2010_530</secondary_id>
    <nct_id>NCT01114490</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)</brief_title>
  <official_title>A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC(0 to infinity)) of anacetrapib</measure>
    <time_frame>through 168 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of a single dose administration of 100mg anacetrapib, measured by the number of clinical and laboratory adverse events</measure>
    <time_frame>through 14 days post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Part 1 - Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moderate Hepatic Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 - Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild Hepatic Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anacetrapib</intervention_name>
    <description>single dose administration of anacetrapib (MK0859) 100 mg oral tablet</description>
    <arm_group_label>Part 1 - Group 1</arm_group_label>
    <arm_group_label>Part 1 - Group 2</arm_group_label>
    <arm_group_label>Part 2 - Group 1</arm_group_label>
    <arm_group_label>Part 2 - Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects of reproductive potential test negative for pregnancy and agree to use
             two acceptable methods of birth control throughout the study

          -  Subject is in good health

          -  Subject agrees to refrain from consumption of red wine, grapefruit, orange and apple
             juices throughout the study

        Exclusion Criteria:

          -  Patient has a history of cancer

          -  Patient is a nursing mother

          -  Patient is unable to refrain from or anticipates the use of any prescription or
             non-prescription medication during the study

          -  Patient consumes excessive amounts of alcohol or caffeine

          -  Patient has had major surgery, donated blood or participated in another
             investigational study within the past 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Lauring B, Li XS, Liu Y, Corr C, Lazarus N, Cote J, Larson P, Levonas AO, Lasseter KC, Preston RA, Smith WB, Lai E, Wagner JA. Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. J Clin Pharmacol. 2014 Nov;54(11):1247-55. doi: 10.1002/jcph.320. Epub 2014 Jun 6.</citation>
    <PMID>24782116</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2010</study_first_submitted>
  <study_first_submitted_qc>April 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2010</study_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anacetrapib</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

